A group of Seidman Cancer Center University Hospitals begins the first clinical trials of the nation that evaluate Cholesterol (Triglide, Fibricor, Lipofen) as a research and possible treatment for patients with HPV+ cervical and HPV+ head cancer (HNSCC). The published preclinical results show that the phenomenon restores the function of the basic tumor suppression gene in these cancers.
The group’s pre-clinical research in cell series and models of HPV+ cancers shows that phenophibrati is also performed against these cancers as conventional chemotherapy with cisplatin. Specifically, Fenofibrate appears to overcome the effects of HPV+ oncroteins and helps to restore the function of the P53 seizure gene function – which is often referred to as a “Guardian of the Genome”.
It is logical that if we can prevent HPV -related oncoproteins from the decrease in levels of P53, we should be able to restore the strong anti -cancer activity of this gene. And this is what we have seen in our preclinical studies. When comparing tissues of tissue of mice that have been treated with phenoprat and mice that have not taken the drug, we see much greater expression of P53 in the mice who have been treated. This medicine puts the genome’s guardian back to work. These are really exciting findings and now we are in the process of promoting with a number of clinical trials started by the researcher to consider if we can use this medicine in cancer patients. “
Wendi Quinn O’Neill, MS, DDS, researcher at UH Seidman Cancer Center and Assistant Professor Otolaryngology at the Western Reserve University School
The research team recently published its preclinical results in the magazine Cancer. Co-authors include: Quintin Pan, PhD, Deputy Research Director at UH Seidman Cancer Center and Professor Otolaryngology at Case Western Reserve University School of Medicine and Holder of the Dr. Lester E. Coleman, Jr. President of Cancer Research & Therapeutics, holder of Chair Jane and Lee Seidman in cancer innovation, among others.
Interestingly, Dr. O’Neill says that Fenofibrate also seems to “reprogram” the microenvail of the HPV+ volume in a way that could prove to be beneficial.
“We really do not understand the exact mechanism responsible, but when we treated the fenofibrate mice, we found that the tumors had collections of immunocytes that penetrate the volume,” he says. “In some cases, we only saw one piece of fibrous tissue and inflammatory cells where the tumor was. In one case there was no detectable sign of the original volume.
The research team from the UH Seidman Cancer Center is the first to document Fenofibrate’s anti -cancer potential to reactivate the P53 into HPV+cancer cells, says Dr. O’Neill. To use and implement these important findings, two phase 1 “window” tests, one registered patients with cervical cancer HPV+ and the other with HPV+ HNSCC, will soon start at the UH Seidman Cancer Center. Patients will take the Fenofibrate research medicine in the window between diagnosis and definitive surgical treatment and then analyzed their blocked tissue to determine whether changes in the cellular pathways observed in previous laboratory experiments are also available in real patients. Neither does the clinical trial test the Fenofibrate at a therapeutic dose – which will occur if the results from the initial window tests are promising, says Dr. O’Neill.
Many are still unknown. However, if it turns out to be effective, Fenofibrate therapy has the potential to be a more targeted and less toxic treatment for HPV -associated cancer patients – as opposed to those with head and neck cancer and alcohol. Such targeted therapeutic approaches are currently missing, says Dr. O’Neill.
“Despite the many features of HPV+ HNSCC. Current treatment options for both forms of the disease are the same regardless of the HPV condition,” he says. “But HPV+ HNSCC is truly a separate disease with a very specific driver, which are these HPV -related oncroteins. We consider theoretically, we should be able to deal with it with a targeted approach that specifically affects viral vibrate oncrotein procedures.
It is likely that Fenofibrate can also play a role in preventing these cancers, says Dr. O’Neill.
“Therapy with phenophibrati alone or in combination with cisplatin or anti-PD-1 checkboat inhibitor could provide a means of targeting the unique biology of HPV+cancers, while reducing the toxicity and morbidity associated with the current standard of treatment.” “In addition, given the excellent security file, Fenofibrate offers the fascinating potential for long -term use as a preventive factor for people who are at high risk for the development of primary or recurrent HPV+”.
The Kathy and Les Coleman Clinical Test Center at UH Seidman Cancer Center offers more than 400 clinical trials for cancer patients.
